Upgrade to Buy Indegene Ltd for the Target Rs 708 by Motilal Oswal Financial Services Ltd
Life science and pharma opex outsourcing a key tailwind
* Global life science and pharma companies prefer to onboard external agencies like Indegene to reduce operational costs, accelerate go-tomarket, access specialized global talent, and manage the spike in content volume during the drug launch and drop during periods with no updates. Agencies can scale up or down teams instantly without the friction of hiring or layoffs.
* Internal medical, legal and regulatory (MLR) reviews are notorious for creating content traffic jams, delaying campaigns by weeks or months. Dedicated external vendors like Indegene streamline the tagging, referencing and pre-review prep.
* Global drug launches require content tailored to different countries, each with its own strict laws. External agencies often have local compliance experts who know exactly what individual govt health departments require.
* By using global agencies with teams across different time zones (e.g., US, Europe and India), content can be drafted, formatted and pre-vetted around the clock, drastically shortening approval cycles.
* The MLR RFP process begins with internal planning and scoping to define capacity gaps, timelines and compliance requirements, which are then used to draft the formal RFP document detailing brand context, software needs and evaluation scorecards. Next, the project team handles vendor sourcing and Q&A by executing NDAs and distributing the RFP to a vetted shortlist of pharma-compliant agencies. This moves into the proposal evaluation and pitch phase, where vendors are scored on technical capability and put through a live mock regulatory review. Finally, the process concludes with selection and contracting, where teams secure a signed master services agreement and establish strict key performance indicators for turnaround times and accuracy.
Pharma GCCs are a big opportunity not threat
* Top pharma giants have successfully expanded their internal GCC footprints in India for core R&D, clinical analytics, and IT
* However, they were not able to scale up internal captive centers for global commercialization and omnichannel operations amid talent shortages and escalating operational costs.
* Ultimately, they pivoted away from the captive model and selected Indegene as their strategic partner to take over, run and scale up their global commercial operations.
* Notably, many new pharma GCCs are entering India, which will drive a massive wave of outsourcing and GCC-managing work to specialized players like Indegene for enterprise commercial solutions.
Valuation and view
* We believe expanding drug pipelines, increasing clinical trial activity, and new disease areas are increasing complexity for life sciences companies, while regulatory and affordability pressures are tightening budgets and timelines. This is accelerating outsourcing, as pharma shifts internal focus to core R&D. In this environment, integrated players like Indegene with capabilities across clinical, regulatory, medical, and commercial operations are well placed to capture growing demand and strengthen their strategic role with clients.
* Operationally, Indegene remains in the top quartile, given superior revenue per employee (higher than IT services peers and ~3x more than the healthcare BPO peers). We estimate a CAGR of ~19%/29%/27% in revenue/EBIT/PAT in INR terms over FY26-28. EBITDA margin is set to recover to 19-20% by 4QFY27, aided by operating leverage.
* We upgrade our rating to BUY from Neutral with a TP of INR708 (based on 25x FY28E EPS)
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
